dc.contributor.author | Lopez, Daniel | |
dc.contributor.author | García-Peydró, Marina | |
dc.date.accessioned | 2024-07-03T06:40:26Z | |
dc.date.available | 2024-07-03T06:40:26Z | |
dc.date.issued | 2024-01 | |
dc.identifier.citation | Biomedicines. 2024;12(1):62. | es_ES |
dc.identifier.issn | 2227-9059 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19920 | |
dc.description.abstract | SARS-CoV-2 caused the devastating COVID-19 pandemic, which, to date, has resulted in more than 800 million confirmed cases and 7 million deaths worldwide. The rapid development and distribution (at least in high-income countries) of various vaccines prevented these overwhelming numbers of infections and deaths from being much higher. But would it have been possible to develop a prophylaxis against this pandemic more quickly? Since SARS-CoV-2 belongs to the subgenus sarbecovirus, with its highly homologous SARS-CoV-1, we propose here that while SARS-CoV-2-specific vaccines are being developed, phase II clinical trials of specific SARS-CoV-1 vaccines, which have been in the pipeline since the early 20th century, could have been conducted to test a highly probable cross-protection between SARS-CoV-1 and SARS-CoV-2. | es_ES |
dc.description.sponsorship | This research was funded by the Spanish Ministry of Science and Innovation by “Acción Estratégica en Salud” MPY 388/18 to D.L. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HLA | es_ES |
dc.subject | Vaccines | es_ES |
dc.subject | Cross-reactivity | es_ES |
dc.subject | T cells | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.title | Could SARS-CoV-1 Vaccines in the Pipeline Have Contributed to Fighting the COVID-19 Pandemic? Lessons for the Next Coronavirus Plague | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38255169 | es_ES |
dc.format.volume | 12 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 62 | es_ES |
dc.identifier.doi | 10.3390/biomedicines12010062 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/biomedicines12010062 | es_ES |
dc.identifier.journal | Biomedicines | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MPY388/18 | es_ES |